Key Figures Q3 2020
|
SEK m, unless otherwise stated |
2020 Jul-Sep |
2019 Jul-Sep |
2020 Jan-Sep |
2019 Jan-Sep |
2019 Jan-Dec |
2019-2020 Jul-Sep Δ |
|
Net revenues |
150.3 |
231.2 |
504.4 |
606.7 |
844.8 |
-35% |
|
Cost of goods sold |
-14.5 |
-25.9 |
-54.3 |
-82.5 |
-105.6 |
-44% |
|
Operating expenses |
-165.4 |
-99.4 |
-459.0 |
-364.5 |
-508.0 |
66% |
|
EBIT |
-29.6 |
105.9 |
-8.9 |
159.7 |
231.2 |
-128% |
|
EBIT margin, % |
-19.7 |
45.8 |
-1.8 |
26.3 |
27.4 |
-65,5 ppt |
|
EBITDA |
-12.2 |
114.1 |
17.9 |
186.3 |
272.1 |
-111% |
|
Earnings per share, before dilution, SEK |
-2.45 |
3.22 |
-1.00 |
5.21 |
6.33 |
-137% |
|
Earnings per share, after dilution, SEK |
-2.45 |
3.16 |
-1.00 |
5.10 |
6.20 |
-138% |
|
Cash flow from operating activities |
-12.9 |
135.7 |
28.0 |
230.7 |
287.0 |
-110% |
|
Cash and cash equivalents |
593.3 |
812.9 |
593.3 |
812.9 |
816.8 |
-27% |
Net revenues and EBIT per segment Q3 2020
|
SEK m |
Revenues |
EBIT |
||||||||
|
|
2020 Jul-Sep |
2019 Jul-Sep |
2020 Jan-Sep |
2019 Jan-Sep |
2019 Jan-Dec |
2020 Jul-Sep |
2019 Jul-Sep |
2020 Jan-Sep |
2019 Jan-Sep |
2019 Jan-Dec |
|
ZUBSOLV® US |
143.8 |
182.7 |
480.2 |
528.7 |
719.2 |
- |
- |
- |
- |
- |
|
US Pharma – total |
143.8 |
182.7 |
480.2 |
528.7 |
719.2 |
72.4 |
90.9 |
237.2 |
242.6 |
347.1 |
|
Digital Therapeutics |
- |
- |
- |
- |
- |
-62.5 |
- |
-110.1 |
- |
-0.9 |
|
Digital Therapeutics– total |
- |
- |
- |
- |
- |
-62.5 |
- |
-110.1 |
- |
-0.9 |
|
Abstral® royalties |
2.5 |
42.4 |
14.6 |
66.3 |
112.6 |
- |
- |
- |
- |
- |
|
Edluar® royalties |
4.0 |
6.1 |
9.5 |
10.2 |
11.6 |
- |
- |
- |
- |
- |
|
ZUBSOLV® - ex US |
- |
- |
0.1 |
0.1 |
0.1 |
- |
- |
- |
- |
- |
|
OX-MPI |
- |
0.1 |
- |
1.4 |
1.4 |
- |
- |
- |
- |
- |
|
HQ & Pipeline segment – total |
6.5 |
48.6 |
24.2 |
78.0 |
125.6 |
-39.5 |
15.0 |
-136.0 |
-82.9 |
-115.0 |
|
Total |
150.3 |
231.2 |
504.4 |
606.7 |
844.8 |
-29.6 |
105.9 |
-8.9 |
159.7 |
231.2 |
Cash flow Q3 2020
|
SEK m |
2020 Jul-Sep |
2019 Jul-Sep |
2020 Jan-Sep |
2019 Jan-Sep |
2019 Jan-Dec |
|
Cash flow from operating activities |
-12.9 |
135.7 |
28.0 |
230.7 |
287.0 |
|
Investment activities |
-50.2 |
-14.5 |
160.9 |
-15.3 |
-22.4 |
|
Financing activities |
-4.2 |
-36.9 |
-106.9 |
-49.4 |
-53.7 |
|
Cash flow (excl exchange rate differences) |
-67.4 |
84.3 |
-239.1 |
166.0 |
210.8 |
|
Liquid funds |
593.3 |
812.9 |
593.3 |
812.9 |
816.8 |
